selinexor (Xpovio) Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA Accelerated Approval FDA Priority Review FDA
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Selinexor (KPT-330) is a first in class XPO1 antagonist being evaluated in multiple later stage clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies.   NCATS

Chemistry

  • SMILES: FC(F)(F)C1=CC(=CC(=C1)C2=NN(C=N2)\C=C/C(=O)NNC3=NC=CN=C3)C(F)(F)F
  • InChIKey: DEVSOMFAQLZNKR-RJRFIUFISA-N
  • Mol. Mass: 443.306
  • ALogP: 3.39
  • ChEMBL Molecule:
    selinexor  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

United States

$2705.8775 - $5306.5325
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

kcp-330 | kpt-330 | selinexor

Organizations (74)

Research & Development (74)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (73)

Approved Indications (2)


 

Lymphoma, Large B-Cell, Diffuse (approved 2020)

Multiple Myeloma (approved 2019)

Experimental Indications - Clinical Trial Phases 1-4 (73)


 

Amyloid (Early Phase 1)

Amyloidosis (Early Phase 1)

Astrocytoma (Phase 1/Phase 2)

Brain Neoplasms (Phase 1)

Breast Neoplasms (Phase 2)

Carcinoma, Hepatocellular (Phase 1)

Carcinoma, Neuroendocrine (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)

Carcinoma, Renal Cell (Phase 1)

Carcinoma, Squamous Cell (Phase 2)

Carcinoma, Transitional Cell (Phase 1/Phase 2)

Castration (Phase 2)

Colorectal Neoplasms (Phase 2)

Coronavirus Infections (Phase 2)

COVID-19 (Phase 3)

Diabetic Foot (Phase 1/Phase 2)

Diffuse Intrinsic Pontine Glioma (Phase 1/Phase 2)

Drug Misuse (Phase 1/Phase 2)

Drug-Related Side Effects and Adverse Reactions (Phase 1/Phase 2)

Endometrial Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 1)

Fallopian Tube Neoplasms (Phase 1)

Gastrointestinal Stromal Tumors (Phase 1/Phase 2)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Gliosarcoma (Phase 1)

Hamartoma (Phase 1)

Hematologic Neoplasms (Phase 1)

Immunoglobulin Light-chain Amyloidosis (Early Phase 1)

Leiomyosarcoma (Phase 1)

Leukemia (Phase 1/Phase 2)

Leukemia, Hairy Cell (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myeloid, Chronic-Phase (Phase 1)

Leukemia, Prolymphocytic (Phase 1)

Liposarcoma (Phase 3)

Lung Neoplasms (Phase 1/Phase 2)

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Lymphoma, B-Cell, Marginal Zone (Phase 1/Phase 2)

Lymphoma, Follicular (Phase 1/Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2/Phase 3)

Lymphoma, Large-Cell, Immunoblastic (Phase 1)

Lymphoma, Mantle-Cell (Phase 1/Phase 2)

Lymphoma, Non-Hodgkin (Phase 1/Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 1)

Maximum Tolerated Dose (Phase 1/Phase 2)

Melanoma (Phase 2)

Multiple Myeloma (Phase 3)

Myelodysplastic Syndromes (Phase 2)

Neoplasm Metastasis (Phase 1/Phase 2)

Neoplasms (Phase 3)

Nerve Sheath Neoplasms (Phase 1)

Neurofibrosarcoma (Phase 1)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 1/Phase 2)

Polycythemia Vera (Phase 2)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Primary Myelofibrosis (Phase 2)

Prostatic Neoplasms (Phase 2)

Rectal Neoplasms (Phase 1)

Respiratory Tract Infections (Phase 3)

Sarcoma (Phase 1)

Sarcoma, Alveolar Soft Part (Phase 1)

Sarcoma, Endometrial Stromal (Phase 1)

Sarcoma, Ewing (Phase 1)

Small Cell Lung Carcinoma (Phase 2)

Stomach Neoplasms (Phase 1)

Thymoma (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Waldenstrom Macroglobulinemia (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 123
  • # of Trial Organizations: 74

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue